Nerve-Sparing Postchemotherapy Retroperitoneal Lymph Node Dissection (PC RPLND) for Nonseminomatous Germ Cell Tumour: Experience from a Tertiary Cancer Centre.
Anand RajaKanuj MalikN KathiresanVenkatraman RadhakrishnanPublished in: Indian journal of surgical oncology (2021)
Postchemotherapy RPLND remains an integral part of management of testicular tumours. Nerve-sparing techniques can minimize the ejaculatory dysfunction due to the procedure. We report our functional and oncological outcomes for nerve-sparing RPLND in postchemotherapy settings. We analysed data from all patients undergoing nerve-sparing PC RPLND from January 1990 to December 2013 at our institute. Antegrade ejaculation and fertility issues were determined by patient history. Nerve sparing was achieved in 30% of patients undergoing PC RPLND. Of the 33 patients who underwent nerve-sparing PC RPLND, 19 (57.8%) had antegrade ejaculation. The mean time to antegrade ejaculation was 6.8 months. After a median follow-up of 75.61 months, 5-year disease-free survival was 98%. Nerve-sparing RPLND can improve functional outcomes without increasing recurrence rates in post chemotherapy setting.
Keyphrases
- robot assisted
- germ cell
- patients undergoing
- peripheral nerve
- free survival
- minimally invasive
- squamous cell carcinoma
- rectal cancer
- prostate cancer
- end stage renal disease
- type diabetes
- radiation therapy
- oxidative stress
- metabolic syndrome
- case report
- prognostic factors
- machine learning
- big data
- papillary thyroid
- locally advanced
- electronic health record
- radical prostatectomy
- artificial intelligence
- patient reported
- neoadjuvant chemotherapy